Investigators for the phase 3 LAURA trial reported that for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring an EGFR mutation after chemoradiotherapy, osimertinib significantly prolonged progression-free survival (PFS) versus a placebo. The study appears in The New England Journal of Medicine (doi:10.1056/NEJMoa2402614).

“This is the first randomized trial conducted specifically for patients with unresectable stage III lung cancer with EGFR mutation,” says Suresh S. Ramalingam, MD, professor of hematology and medical oncology and executive director of the Winship Cancer Institute at the Emory University School of Medicine and LAURA trial investigator. “The study shows a clear benefit with osimertinib compared to placebo in terms of progression-free survival and lower risk of brain progression.”

Study results show that treatment with osimertinib reduced the risk of progression or death by 84% in comparison with the placebo. The study was presented during a press briefing at the 2024 annual meeting of the American Society of Clinical Oncology held in Chicago, Illinois.

3 期 LAURA 试验的研究人员报告称，对于放化疗后携带EGFR突变的不可切除的 III 期非小细胞肺癌 (NSCLC) 患者，与安慰剂相比，奥希替尼显着延长了无进展生存期 (PFS)。该研究发表在《新英格兰医学杂志》上 (doi:10.1056/NEJMoa2402614)。

“这是第一个专门针对患有EGFR突变的不可切除的 III 期肺癌患者进行的随机试验，”埃默里大学医学院血液学和肿瘤内科教授兼 Winship 癌症研究所执行主任 Suresh S. Ramalingam 医学博士说。医学和 LAURA 试验研究者。 “该研究表明，与安慰剂相比，奥西替尼在无进展生存期和降低脑部进展风险方面具有明显的益处。”

研究结果表明，与安慰剂相比，奥希替尼治疗可将疾病进展或死亡风险降低 84%。该研究是在伊利诺伊州芝加哥举行的美国临床肿瘤学会 2024 年年会上的新闻发布会上提出的。